Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of High-fat Diet on the Pharmacokinetics of Globalagliatin (SY-004) in Healthy Subjects
NCT04907006Phase 1Completed
- Sponsor
- Yabao Pharmaceutical Group Co., Ltd.
- Start
- Aug 2021
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of globalagliatin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Yabao Pharmaceutical Group Co., Ltd. Primary endpoints: Area Under the Plasma Concentration-Time Curve from Time Zero to Last Quantifiable Concentration at 8 days, Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity at 8 days and 1 more. Started Aug 2021; status: completed.
02
Drugs
globalagliatin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04907006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04907006.